Eli Lilly Is Being Paid to Give Away Price, The Market Is Fixated on the Wrong Risk
At roughly 25x next year's consensus earnings for a business converting three-quarters of net income to cash and taking share on both sides of the Atlantic, Eli Lilly is mispriced to the upside — and the risk-reward has not turned, it has merely become less generous than it wa...
Read Article ›